Follow Us:




n a new study published in The American Journal of Pathology, scientists say they have identified a biomarker in patients with stomach cancer that starves tumors of their blood supply and reduces the ability of cancer cells to spread to other parts of the body.
[stomach cancer]
In the US, around 24,590 cases of stomach cancer will be diagnosed in 2015.

The new research from China shows that stomach cancer patients whose cancer lesions show high levels of the biomarker microRNA 506 (miR-506) have far longer survival times compared with stomach cancer patients with lower levels of miR-506. Thus, miR-506 is a valuable biomarker to predict stomach cancer survival.

Other benefits of miR-506 include its ability to suppress tumor growth, blood vessel formation and the spread of cancer cells to other parts of the body.

Lead investigator Dr. Xin Song, of the Cancer Research Institute of Southern Medical University and the Cancer Biotherapy Center of The Third Affiliated Hospital of Kunming Medical University - both in China - says that "these findings indicate that miR-506 is necessary and sufficient for angiogenesis suppression during gastric cancer progression."

By way of introducing their research into stomach cancer, the authors begin by explaining that Epithelial-mesenchymal transition (EMT) in cancer cells is associated with an increased capacity to invade into surrounding tissue and migrate to distant sites.

Learn more about stomach cancer

EMT is a key step during normal embryo formation (embryogenesis), but EMT is now also recognized to be involved in processes within the body that result in functional changes associated with cancer (cancer pathophysiology).

While tumor-specific factors that drive EMT are not completely understood, it is known that various biochemical changes take place through EMT to produce "healing-type cells" called mesenchymal cells (MSCs).

In turn, it is MSCs that play an important role both in normal tissue repair as well as disease-causing processes, including tumor growth and the spread of cancer cells.

These transformed cells have the ability to migrate away from the tissues that line the cavities and surfaces of blood vessels and organs throughout the body, invade other tissues and stave off normal programmed cell death (PCD).

One of the several mechanisms that may initiate an EMT is the change in the expression of a specific class of small noncoding RNAs that regulate gene expression. It was one of these - miR-506 - that was identified by the researchers as a useful marker that enabled them to organize the patients they were studying in order of the severity of their stomach cancer.

Dr. Song says the research team considered the hypothesis that miR-506 acts as a suppressor of how cancer cells spread using a system level and integrative approach.
Tumor samples taken from people who had undergone cancer surgery

In a blind test, the researchers used a form of genetic analysis called polymerone chain reaction (PCR) to detect miR-506 in human gastric samples taken from 84 people who had undergone cancer surgery. The researchers analyzed the miR-506 levels in each of these samples, and patients were allocated to different groups based on whether they were above or below the mean miR-506 level.

This is when the team found that survival among patients with signs of high miR-506 was significantly longer.

At 60 months, for example, cumulative survival was approximately 30% in the low-miR-506 expression group, compared with 80% in the high-expression group.

The research team then looked at signs of miR-506 in seven stomach cancer cell lines. Here, it was found that stomach cancer cells had lower levels of miR-506 than normal stomach tissue.

Analysis of cells grown in vitro then showed that miR-506 levels were lowest in the cell lines that had the highest invasive activity, and the highest levels were seen in cell lines with the lowest invasive activity.

Further research and experiments strengthened the hypothesis that miR-506 acts as a suppressor of how cancer cells spread.




Subsidiary Companies




Yaghoot Rooyan International Holding consists of 30 special and international companies in the field of pharmaceutical, biologic products(specially Vaccines and Peptides), medical devices herbal and natural medicines,

nutrition supplements, hair and skin special products, medical equipment and herbal-based cosmetics products.